Tisdag 12 November | 13:56:43 Europe / Stockholm

Kalender

Tid*
2024-12-17 - Årsstämma
2024-11-14 - Bokslutskommuniké 2024
2024-11-12 - Extra Bolagsstämma 2024
2024-08-15 - Kvartalsrapport 2024-Q3
2024-05-30 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q2
2024-03-01 - X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 - Bokslutskommuniké 2023
2024-02-14 - Kvartalsrapport 2024-Q1
2023-12-15 - X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 - Kvartalsrapport 2023-Q3
2023-05-17 - Kvartalsrapport 2023-Q2
2023-04-14 - Extra Bolagsstämma 2023
2023-02-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Årsstämma
2023-02-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 - Bokslutskommuniké 2022
2022-08-13 - Kvartalsrapport 2022-Q3
2022-05-20 - Kvartalsrapport 2022-Q2
2022-02-18 - Kvartalsrapport 2022-Q1
2021-12-10 - X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 - Årsstämma
2021-11-18 - Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-10-12 14:00:32

CS MEDICA is thrilled to announce that the Indian State's FDA has granted official approval for two cosmetic products to be marketed and sold through its subsidiary, CANNORDIC India Ltd.

CS MEDICA A/S ("CS MEDICA" or "The Company"), a global MedTech company specializing in CBD and pain management, is pleased to announce a significant achievement in its Global expansion. After rigorous scrutiny, the Indian State's FDA has granted approval for two cosmetic products with CBD from CS MEDICA, the CANNASEN[®] Anti-Hair Loss Serum and CANNASEN[®] PSOR+Atopic Lotion.

Kamlesh Vora, Managing Director at Cannordic India Pvt Ltd, states

"Securing Indian FDA approval for these cosmetic products is just the beginning of our journey in India. We're poised to introduce CS MEDICA's medical innovations, set to redefine the industry, pioneer innovation, and enhance well-being throughout India."

Market Highlights:
The hair loss market in India, with a market size of over 10,000 crore INR (approximately 12 billion DKK), represents a substantial segment where individuals seek effective solutions to combat various types of hair loss, from hereditary to stress-related hair loss.

In the skin atopic lotion market, India boasts a market size of more than 5,000 crore INR (around 6 billion DKK). This market caters to consumers actively seeking dermatologist-recommended products, especially those designed to alleviate conditions like psoriasis, dry, and atopic skin.

Product Highlights:
CANNASEN® Anti-Hair Loss Serum
CANNASEN® Anti-Hair Loss Serum offers a comprehensive and natural solution for those battling hair loss. This clinically tested hair serum features patented ingredients, including Redensyl®, Capixyl®, and CBD (cannabidiol). It is designed to address various types of hair loss, promoting stronger hair growth and thicker strands, while enhancing scalp health.

CANNASEN® PSOR+Atopic Lotion
CANNASEN® PSOR+Atopic Lotion is a moisturizing and natural solution, specifically formulated for daily care of psoriasis, dry skin, and atopic skin. It effectively reduces itching, soothes tight skin, and diminishes redness while improving overall skin texture.